Log in
Enquire now
AmorChem

AmorChem

AmorChem is an early-stage, venture capital fund focused on creating life science companies.

OverviewStructured DataIssuesContributors

Contents

amorchem.com
Is a
Company
Company
Investor
Investor
Organization
Organization
Venture capital firm
Venture capital firm

Company attributes

Industry
Biology
Biology
Biopharmaceutical
Biopharmaceutical
Technology
Technology
Biotechnology
Biotechnology
Location
Canada
Canada
Montreal, Quebec
Montreal, Quebec
B2X
B2B
B2B
CEO
Elizabeth Douville
Elizabeth Douville
Founder
Elizabeth Douville
Elizabeth Douville
Email Address
info@amorchem.com
Phone Number
+5142833602
+15148497696

Venture Capital Firm attributes

Invested in
Liminal BioSciences Inc.
Liminal BioSciences Inc.
0
Inversago Pharma
Inversago Pharma
SpecificiT Pharma
SpecificiT Pharma
Semathera Inc
Semathera Inc

Other attributes

Company Operating Status
Active
Contact Page URL
amorchem.com

AmorChem is a leading early stage venture fund dedicated to creating the next generation of biotech companies from academic research.AmorChem aims to be the premier early stage venture fund in Canada by building an active and collaborative community of biotech start-ups from academic research and fostering a new generation of passionate science entrepreneurs. The company invests mainly in projects that originate at Quebec-based universities and research centers.

The AmorChem fund model combines access to financial resources with a virtual incubator structure. The first fund of 41.2M$ was a portfolio of 24 technologies and resulted in two pharma exits and five spin-out companies. The AmorChem II Fund was launched in 2017 and as of January 2019 totalled $53.7M.

AmorChem holds the AmorChem Knock Out event, inspired by the television show Dragons’ Den, where researchers compete for $500,000 in financing. Their fifth event was hosted on April 24, 2019.

Projects funded

AmorChem announced in January, 2019, the closing of its first financing of a university project focused on RNA Zipcodes, short sequences of RNA that control their intracellular transport. The project is a collaboration is between Univalor, Dr Éric Lécuyer of the Montreal Clinical Research Institute (“IRCM”), Dr. Mathieu Blanchette and Dr. Jérôme Waldispühl of McGill University.

In February 2019, AmorChem II announced financing of a project on the SRSF3 target, which regulates RNA splicing, transport and gene expression and plays a role analogous to checkpoint inhibition in the innate immune system. Removal of the off-switch in the innate immune response could lead to new therapeutic approaches for neuroinflammatory diseases. The funding will support work in the laboratory of Dr. Jasna Kriz in an agreement with Université Laval and the CERVO Brain Research Centre of the CIUSSS de la Capitale Nationale.

Timeline

No Timeline data yet.

Associated Investment Funds

Accelerator Batches

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like AmorChem

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.